Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Clin Toxicol  ; 53(4): p.281-2, 2015.
Artigo em Inglês | Sec. Est. Saúde SP, SESSP-IBPROD, Sec. Est. Saúde SP | ID: but-ib10253
2.
Clin Exp Rheumatol ; 30(1): 132-6, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22325053

RESUMO

OBJECTIVES: To analyse the use of complementary and alternative medicine (CAM) in children with rheumatic diseases, treated at a paediatric rheumatology centre in Italy. METHODS: Parents of children with different kinds of chronic rheumatic diseases anonymously completed a questionnaire about their children's past or current use of CAM. Two groups of patients were analysed: Group A consisted of children who were still attending the centre; Group B consisted of children who had not attended the clinic for more than one year. RESULTS: 150 completed surveys were analysed: 22 paediatric patients (14.7%), 10/100 in group A and 12/50 in group B, used CAM to treat their diseases. The therapies used the most were homeopathy, herbal remedies, vitamins and minerals. We observed a significantly greater use of CAM among patients who had not attended the clinic for more than one year (24%) as compared to those who were regularly checked (10%) (p=0.02). Parents' use of CAM was significantly related to its use for their children (p=0.001). A poor outcome, probably related to the exclusive use of alternative treatments, was observed in three out of six patients who had completely stopped using traditional immunosuppressive drugs. CONCLUSIONS: Physicians should be aware of the use of CAM particularly in patients who skip their regular check-ups. The use of CAM to treat childhood rheumatic conditions in Italy seems to be less frequent than in North America.


Assuntos
Terapias Complementares/estatística & dados numéricos , Doenças Reumáticas/tratamento farmacológico , Criança , Feminino , Inquéritos Epidemiológicos , Humanos , Itália , Masculino , Pediatria , Reumatologia , Inquéritos e Questionários
3.
Pathophysiol Haemost Thromb ; 37(1): 1-16, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20714126

RESUMO

Despite the nearly worldwide distribution of Lepidoptera, there are few species with clear documentation of adverse reactions in humans. Most syndromes caused by Lepidoptera are consequences of direct contact with the hairs or setae of caterpillars. In most instances, the adverse effects caused by moth and caterpillars are self-limited and the treatment is based on the removal of hairs, application of topical antipruritics and, in some cases, the use of oral antihistamines. However, in the case of envenoming by South American Lonomiaobliqua caterpillars, the antilonomic serum produced at Instituto Butantan in Brazil is the only effective treatment to re-establish the physiological coagulation parameters in poisoned patients and to abolish the complications seen in severe cases (e.g. consumptive coagulopathy, intracerebral hemorrhage, and acute renal failure). Many studies have been carried out to understand the pathophysiological mechanism of envenoming by L. obliqua. Several toxic principles were found in bristle extract and the hemolymph, probably related to the envenoming. An interesting fact is that some toxins from the venom usually have more than one function. With the advent of molecular biology techniques it has become possible to analyze these processes at a molecular level, thus giving rise to hypotheses on the molecular basis of envenomation. This review contributes to enhance our understanding of the dramatic alterations that hemorrhagic syndrome causes in patients, current treatment, and the diversity of the molecules involved in this pathology.


Assuntos
Venenos de Artrópodes/toxicidade , Coagulação Sanguínea/efeitos dos fármacos , Hemorragia/etiologia , Mariposas/química , Serina Endopeptidases/toxicidade , Animais , Venenos de Artrópodes/química , Humanos , Larva/química , Serina Endopeptidases/química
6.
Rheumatology (Oxford) ; 47(10): 1510-4, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18676502

RESUMO

OBJECTIVE: To describe efficacy and safety of infliximab in the treatment of childhood chronic uveitis during a long-term follow-up. METHODS: Fifteen patients (median age 12 yrs, range 5-21 yrs) with chronic uveitis were enrolled. Before infliximab treatment, children had presented active uveitis despite treatment with MTX and/or CSA. All were also receiving oral prednisone (1-2 mg/kg/day) for at least 1 month. Infliximab (5 mg/kg) was administered at weeks 0, 2, 6 and then every 6-8 weeks. Later on, in patients enrolled in Florence the administration interval was progressively increased up to 10 weeks if uveitis did not flare, whilst in children from Padua the scheduled infusion rate was maintained every 6 weeks. Absence or recurrence rate of uveitis up to the last visit was recorded. RESULTS: Median follow-up on treatment was 30 months (range 16-38 months), median number of infusions 22 (range 11-30). During the first year, 13/15 children achieved a complete remission over a median period of 10 weeks, but all relapsed thereafter. The probability of a first relapse was correlated to length of treatment, once remission was achieved (P < 0.03). The total number of relapses correlated with the duration of treatment (r(s) = 0.81; P < 0.002) and with the total number of infusions (r(s) = 0.83; P < 0.001). The total number of relapses on treatment at last follow-up was not significantly different between the two centres. CONCLUSIONS: Even if limited to a small group, infliximab appears to be an effective treatment for uveitis in children, but its efficacy seems to wane over time.


Assuntos
Anti-Inflamatórios/administração & dosagem , Anticorpos Monoclonais/administração & dosagem , Uveíte/tratamento farmacológico , Adolescente , Anti-Inflamatórios/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Criança , Pré-Escolar , Doença Crônica , Esquema de Medicação , Resistência a Medicamentos , Feminino , Seguimentos , Humanos , Lactente , Infliximab , Masculino , Estudos Prospectivos , Recidiva , Indução de Remissão , Resultado do Tratamento , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Uveíte/fisiopatologia , Acuidade Visual/efeitos dos fármacos
8.
Trans R Soc Trop Med Hyg ; 92(5): 546-8, 1998.
Artigo em Inglês | MEDLINE | ID: mdl-9861376

RESUMO

A clinical and epidemiological study of 267 cases of envenomation by Loxosceles spp. (loxoscelism), notified to Centro de Informações Toxicológicas de Florianópolis (Santa Catarina State, Brazil), was conducted between January 1985 and December 1995. Most of the incidents occurred along the coast of the mid-southern region of the state, during the warmest months. L. laeta and L. intermedia were identified as the causative agents. Cutaneous loxoscelism was clinically diagnosed in 232 (86.9%) patients with local pain (86.5%), oedema (80.5%), hyperaemia (79.8%) and necrosis (56.9%). Cutaneous-visceral loxoscelism was detected in 35 patients (13.1%) with intravascular haemolysis, manifested by jaundice (68.6%), oliguria (45.7%), dark urine (28.6%), haemorrhage (25.7%), anuria (8.6%) and shock (2.9%), besides the cutaneous effects. Specific antivenom was given to 125 patients (46.8%) and only 8 (6.5%) had mild reactions. Acute renal failure was observed in 17 cases (6.4%); 4 patients (1.5%) died, all of whom were children under 14 years old.


Assuntos
Picada de Aranha/epidemiologia , Venenos de Aranha/intoxicação , Injúria Renal Aguda/etiologia , Adolescente , Adulto , Antivenenos/efeitos adversos , Antivenenos/uso terapêutico , Vesícula/etiologia , Brasil/epidemiologia , Criança , Feminino , Humanos , Icterícia/etiologia , Masculino , Estudos Retrospectivos , Úlcera/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...